FDA Approves Inspire Therapy Expansion for Specific Pediatric Population
Inspire intends to immediately begin educating healthcare providers across the US about the benefits of Inspire therapy for this population of children.
Inspire intends to immediately begin educating healthcare providers across the US about the benefits of Inspire therapy for this population of children.
EnsoData will accelerate expansion and commercial distribution partnerships, continue building its team, and expand its offerings.
A new telemetry cable enables Bluetooth connectivity to the programmer tablet. The platform interfaces with Inspire Cloud.
A second chance for many patients, devices like Inspire and remede also facilitate new avenues for marketing.
Read MoreInspire’s core objective with this report is to allow its customers to make informed decisions related to the best treatment options.
Read MoreCMS will review the panel’s recommendations, and the final rules will be published later in 2021.
Read MoreA flow chart from Sleep 360 Sleep Diagnostic Center illustrates the OSA patient journey from referral to customized therapy.
Read MoreMany patients give up on CPAP because they can’t tolerate the machine. Implanted neurostimulators may help, but, like positive airway pressure, these new devices can take some getting used to.
Read MoreThis positive coverage decision provides additional OSA patients who are unable to benefit from CPAP the opportunity to gain access to Inspire therapy.”
Read MoreInspire and Japan Lifeline Co Ltd worked closely with the Minister of Health Labour and Welfare to advance the reimbursement application for Inspire therapy, which was approved by an expert panel this month.
Read MoreIt’s been an unusual year. But, mostly as usual, the US Food & Drug Administration continued to review device and drug applications across all fields of medicine.
Read MorePanelists discuss proper patient selection, preparation for device evaluation and the procedure, and post-implant adjustments.
Read MoreAfter more than 20 years of troubled sleep, Dwight Johnson can finally sleep peacefully throughout the night.
Read MoreHealth plan provider Humana Inc will provide coverage for Inspire upper airway stimulation therapy, effective August 27.
Read MoreThe reimbursement process is anticipated to be completed during 2021 and Inspire expects to launch its therapy in Australia thereafter.
Read MorePhysicians who use Inspire upper airway stimulation, Respicardia’s remedē, and Avery’s diaphragm pacemaker share their stories.
Read MoreInspire has multiple additional digital health solutions in development that are aimed at improving patient outcomes and medical practice efficiency.
Read MoreThe US Food and Drug Administration (FDA) has approved an expanded age range for Inspire Upper Airway Stimulation Therapy for obstructive sleep apnea to include 18-21 year old patients.
Read More